ABSI
NASDAQ · Biotechnology
Absci Corp
$9.16
+1.75 (+23.62%)
Open$8.45
Previous Close$7.41
Day High$10.85
Day Low$8.45
52W High$8.17
52W Low$2.24
Volume—
Avg Volume5.17M
Market Cap1.16B
P/E Ratio—
EPS$-0.83
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+157.1% upside
Current
$9.16
$9.16
Target
$23.55
$23.55
$16.79
$23.55 avg
$35.63
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.26M | 4.15M | 58.57M |
| Net Income | -134,000,206 | -153,298,824 | -8,944,093 |
| Profit Margin | -4,113.7% | -3,908.0% | -15.3% |
| EBITDA | -126,314,409 | -152,534,242 | -15,160,350 |
| Free Cash Flow | — | — | -10,726,027 |
| Rev Growth | -21.3% | -21.3% | +10.3% |
| Debt/Equity | 0.00 | 0.00 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |